{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T12:13:03Z","timestamp":1648642383742},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Interventional Cardiology Clinics"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.iccl.2012.12.004","type":"journal-article","created":{"date-parts":[[2013,1,24]],"date-time":"2013-01-24T12:15:29Z","timestamp":1359029729000},"page":"273-282","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacotherapy During Saphenous Vein Graft Intervention"],"prefix":"10.1016","volume":"2","author":[{"given":"Willis M.","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Michael","family":"Lincoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.iccl.2012.12.004_bib1","doi-asserted-by":"crossref","first-page":"102C","DOI":"10.1016\/0002-9149(84)90759-8","article-title":"Progression of atherosclerosis in coronary arteries and bypass grafts: ten years later","volume":"53","author":"Bourassa","year":"1984","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.iccl.2012.12.004_bib2","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.jacc.2004.08.064","article-title":"Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs cooperative study","volume":"44","author":"Goldman","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.iccl.2012.12.004_bib3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/1522-726X(200012)51:4<394::AID-CCD4>3.0.CO;2-G","article-title":"Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon","volume":"51","author":"Sdringola","year":"2000","journal-title":"Catheter Cardiovasc Interv"},{"issue":"11","key":"10.1016\/j.iccl.2012.12.004_bib4","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJM199709113371103","article-title":"Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators","volume":"337","author":"Savage","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.iccl.2012.12.004_bib5","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1161\/01.CIR.91.7.1966","article-title":"A\u00a0multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. CAVEAT-II Investigators","volume":"91","author":"Holmes","year":"1995","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.iccl.2012.12.004_bib6","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/0735-1097(95)00217-R","article-title":"Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: the multicenter U.S. Palmaz-Schatz stent experience. The Palmaz-Schatz Stent Study Group","volume":"26","author":"Wong","year":"1995","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.iccl.2012.12.004_bib7","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators","volume":"336","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.iccl.2012.12.004_bib8","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1056\/NEJMoa1109596","article-title":"Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction","volume":"365","author":"Kastrati","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.iccl.2012.12.004_bib9","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation","volume":"330","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.iccl.2012.12.004_bib10","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0002-9149(97)00589-4","volume":"80","author":"Mak","year":"1997","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.iccl.2012.12.004_bib11","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0735-1097(99)00329-0","article-title":"The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions","volume":"34","author":"Mathew","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.iccl.2012.12.004_bib12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijcard.2005.08.010","article-title":"Late outcomes after intervention of vein grafts in diabetics with abciximab use","volume":"111","author":"Applegate","year":"2006","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.iccl.2012.12.004_bib13","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0002-8703(00)90014-0","article-title":"Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts","volume":"139","author":"Barsness","year":"2000","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.iccl.2012.12.004_bib14","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.amjcard.2005.04.044","article-title":"Effect of adjunctive treatment with tirofiban on troponin T elevation during stenting of critically stenosed aortocoronary saphenous vein grafts","volume":"96","author":"Kurowski","year":"2005","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.iccl.2012.12.004_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1620\/tjem.206.7","article-title":"The effect of tirofiban and clopidogrel pretreatment on outcome of old saphenous vein graft stenting in patients with acute coronary syndromes","volume":"206","author":"Ozkan","year":"2005","journal-title":"Tohoku J Exp Med"},{"issue":"24","key":"10.1016\/j.iccl.2012.12.004_bib16","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1161\/01.CIR.0000041250.89627.A9","article-title":"Lack of benefit from intravenous platelet glycoprotein IIb\/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials","volume":"106","author":"Roffi","year":"2002","journal-title":"Circulation"},{"issue":"9122","key":"10.1016\/j.iccl.2012.12.004_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","article-title":"Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade","volume":"352","author":"EPISTENT Investigators","year":"1998","journal-title":"Lancet"},{"issue":"9063","key":"10.1016\/j.iccl.2012.12.004_bib18","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","article-title":"Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.iccl.2012.12.004_bib19","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet glycoprotein IIb\/IIIa in unstable angina: receptor suppression using integrilin therapy","volume":"339","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.iccl.2012.12.004_bib20","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1161\/01.CIR.0000080894.51311.0A","article-title":"Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts","volume":"108","author":"Stone","year":"2003","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.iccl.2012.12.004_bib21","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/eurheartj\/ehi736","article-title":"Platelet glycoprotein IIb\/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection","volume":"27","author":"Jonas","year":"2006","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.iccl.2012.12.004_bib22","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.iccl.2012.12.004_bib23","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMoa0802944","article-title":"Bivalirudin versus unfractionated heparin during percutaneous coronary intervention","volume":"359","author":"Kastrati","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.iccl.2012.12.004_bib24","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.amjcard.2004.01.033","article-title":"Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)","volume":"93","author":"Lincoff","year":"2004","journal-title":"Am J Cardiol"},{"issue":"21","key":"10.1016\/j.iccl.2012.12.004_bib25","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.iccl.2012.12.004_bib26","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.iccl.2012.12.004_bib27","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ccd.20735","article-title":"Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions","volume":"68","author":"Kao","year":"2006","journal-title":"Catheter Cardiovasc Interv"},{"issue":"7","key":"10.1016\/j.iccl.2012.12.004_bib28","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.amjcard.2010.06.003","volume":"106","author":"Kumar","year":"2010","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.iccl.2012.12.004_bib29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.amjcard.2005.02.047","article-title":"Bivalirudin versus heparin as an antithrombotic agent in patients who undergo percutaneous saphenous vein graft intervention with a distal protection device","volume":"96","author":"Rha","year":"2005","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.iccl.2012.12.004_bib30","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.amjcard.2005.01.071","article-title":"Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial)","volume":"95","author":"Madan","year":"2005","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.iccl.2012.12.004_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.292.1.45","article-title":"Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial","volume":"292","author":"Ferguson","year":"2004","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.iccl.2012.12.004_bib32","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1056\/NEJMoa052711","article-title":"Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention","volume":"355","author":"Montalescot","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.iccl.2012.12.004_bib33","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1001\/archinte.167.22.2423","article-title":"Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials","volume":"167","author":"Dumaine","year":"2007","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.iccl.2012.12.004_bib34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0735-1097(02)02631-1","article-title":"Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study","volume":"41","author":"Bhatt","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.iccl.2012.12.004_bib35","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.jacc.2005.12.077","article-title":"A\u00a0randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial","volume":"47","author":"Gibson","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.iccl.2012.12.004_bib36","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0002-9149(99)80225-2","article-title":"Safety and efficacy of extended urokinase infusion plus stent deployment for treatment of obstructed, older saphenous vein grafts","volume":"76","author":"Denardo","year":"1995","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.iccl.2012.12.004_bib37","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0735-1097(95)00448-3","article-title":"Recanalization of chronically occluded aortocoronary saphenous vein bypass grafts with long-term, low dose direct infusion of urokinase (ROBUST): a serial trial","volume":"27","author":"Hartmann","year":"1996","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.iccl.2012.12.004_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0002-9149(97)89224-7","article-title":"Transcatheter therapy of thrombotic-occlusive lesions in saphenous vein grafts","volume":"78","author":"Cecena","year":"1996","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.iccl.2012.12.004_bib39","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ccd.20885","article-title":"Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention","volume":"68","author":"Huang","year":"2006","journal-title":"Catheter Cardiovasc Interv"},{"issue":"5","key":"10.1016\/j.iccl.2012.12.004_bib40","first-page":"202","article-title":"Prophylactic intragraft injection of nicardipine prior to saphenous vein graft percutaneous intervention for the prevention of no-reflow: a review and comparison to protection devices","volume":"23","author":"Habibzadeh","year":"2011","journal-title":"J\u00a0Invasive Cardiol"},{"issue":"2","key":"10.1016\/j.iccl.2012.12.004_bib41","first-page":"58","article-title":"\u201cPharmacologic\u201d distal protection using prophylactic, intragraft nicardipine to prevent no-reflow and non-Q-wave myocardial infarction during elective saphenous vein graft intervention","volume":"19","author":"Fischell","year":"2007","journal-title":"J\u00a0Invasive Cardiol"},{"issue":"11","key":"10.1016\/j.iccl.2012.12.004_bib42","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/01.CIR.0000012783.63093.0C","article-title":"Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts","volume":"105","author":"Baim","year":"2002","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.iccl.2012.12.004_bib43","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.jacc.2005.06.073","article-title":"Randomized evaluation of the TriActiv balloon-protection flush and extraction system for the treatment of saphenous vein graft disease","volume":"46","author":"Carrozza","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.iccl.2012.12.004_bib44","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ccd.1810240414","article-title":"Intracoronary verapamil for the treatment of distal microvascular coronary artery spasm following PTCA","volume":"24","author":"Pomerantz","year":"1991","journal-title":"Cathet Cardiovasc Diagn"},{"issue":"4","key":"10.1016\/j.iccl.2012.12.004_bib45","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ccd.10375","article-title":"Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction","volume":"57","author":"Werner","year":"2002","journal-title":"Catheter Cardiovasc Interv"},{"issue":"6","key":"10.1016\/j.iccl.2012.12.004_bib46","first-page":"299","article-title":"Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial","volume":"14","author":"Michaels","year":"2002","journal-title":"J\u00a0Invasive Cardiol"},{"issue":"5","key":"10.1016\/j.iccl.2012.12.004_bib47","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/0002-8703(92)91040-8","article-title":"Adenosine and its cardiovascular effects","volume":"123","author":"Freilich","year":"1992","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.iccl.2012.12.004_bib48","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/(SICI)1097-0304(199812)45:4<360::AID-CCD1>3.0.CO;2-R","article-title":"Reversal of \u201cno reflow\u201d during vein graft stenting using high velocity boluses of intracoronary adenosine","volume":"45","author":"Fischell","year":"1998","journal-title":"Cathet Cardiovasc Diagn"},{"issue":"5","key":"10.1016\/j.iccl.2012.12.004_bib49","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0735-1097(01)01138-X","article-title":"Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience","volume":"37","author":"Hillegass","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.iccl.2012.12.004_bib50","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ccd.20149","article-title":"Treatment of slow\/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction","volume":"63","author":"Wang","year":"2004","journal-title":"Catheter Cardiovasc Interv"},{"issue":"11","key":"10.1016\/j.iccl.2012.12.004_bib51","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.amjcard.2005.01.082","article-title":"Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction","volume":"95","author":"Pasceri","year":"2005","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.iccl.2012.12.004_bib52","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.ahj.2006.05.010","article-title":"Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial","volume":"152","author":"Amit","year":"2006","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.iccl.2012.12.004_bib53","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1536\/ihj.48.423","article-title":"Selective intracoronary administration of nitroprusside before balloon dilatation prevents slow reflow during percutaneous coronary intervention in patients with acute myocardial infarction","volume":"48","author":"Shinozaki","year":"2007","journal-title":"Int Heart J"},{"issue":"4","key":"10.1016\/j.iccl.2012.12.004_bib54","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ccd.20010","article-title":"Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon","volume":"61","author":"Barcin","year":"2004","journal-title":"Catheter Cardiovasc Interv"},{"issue":"3","key":"10.1016\/j.iccl.2012.12.004_bib55","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/01.RES.68.3.847","article-title":"Mechanisms responsible for the heterogeneous coronary microvascular response to nitroglycerin","volume":"68","author":"Kurz","year":"1991","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.iccl.2012.12.004_bib56","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/(SICI)1097-0304(199610)39:2<113::AID-CCD1>3.0.CO;2-I","article-title":"Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin","volume":"39","author":"Kaplan","year":"1996","journal-title":"Cathet Cardiovasc Diagn"}],"container-title":["Interventional Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745812001745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745812001745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T21:08:07Z","timestamp":1562620087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211745812001745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S2211745812001745"],"URL":"https:\/\/doi.org\/10.1016\/j.iccl.2012.12.004","relation":{},"ISSN":["2211-7458"],"issn-type":[{"value":"2211-7458","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}